Bisacodyl

Identification

Summary

Bisacodyl is a stimulant laxative used for the temporary relief of occasional constipation and cleansing of the colon as a preparation for colonoscopy in adults.

Brand Names

Alophen Reformulated Jan 2008, Bi-peglyte, Bisac-evac, Carters Little Pills, Dulcolax, Fleet Mineral Oil, Gavilyte-H and Bisacodyl

Generic Name

Bisacodyl

DrugBank Accession Number

DB09020

Background

Bisacodyl, a diphenylmethane derivative, is a commonly used over the counter stimulant laxative for occasional constipation.^5,9 Both bisacodyl and picosulfate are metabolized to the same active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM).^4,5,6

Bisacodyl was patented on 25 September 1956⁸ but has been used as a laxative since 1952.⁵

Type

Small Molecule

Groups

Approved

Structure

Similar Structures

Weight: Average: 361.3906
Monoisotopic: 361.131408101
Chemical Formula: C₂₂H₁₉NO₄

Synonyms

Bisacodilo
Bisacodyl
Bisacodyle
Bisacodylum
Phenol, 4,4'-(2-pyridinylmethylene)bis-, diacetate (ester)

External IDs

LA 96 a
LA96a

Pharmacology

Indication

Bisacodyl is indicated to relieve occasional constipation and irregularity.⁹

Reduce drug development failure rates

Build, train, & validate machine-learning models
with evidence-based and structured datasets.

See how

Build, train, & validate predictive machine-learning models with structured datasets.

See how

Associated Conditions

Associated Therapies

Bowel preparation therapy

Contraindications & Blackbox Warnings

Avoid life-threatening adverse drug events

Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.

Learn more

Avoid life-threatening adverse drug events & improve clinical decision support.

Learn more

Pharmacodynamics

Patients should be counselled regarding abdominal pain, nausea, vomiting, or a change in bowel function that lasts longer than 2 weeks.⁹ It has a wide therapeutic index, as patients can take 5-15 mg orally.⁹ Patients taking bisacodyl should be counselled before taking the medication if they are already experiencing abdominal pain, nausea, vomiting, or a change in bowel function lasting longer than 2 weeks.⁹ Patients should also be counselled to stop taking the medication if they experience rectal bleeding or no bowel movement in 12 hours.⁹

Mechanism of action

Bisacodyl is deacetylated to the active bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM) by an intestinal deacetylase.^4,5,6 BHPM can stimulate parasympathetic nerves in the colon directly to increase motility and secretions.⁵

Bisacodyl stimulates adenylate cyclase, increasing cyclic AMP, leading to active transport of chloride and bicarbonate out of cells.⁵ Sodium ions, potassium ions, and water passively leave the cell; while sodium and chloride ions are unable to be reabsorbed.⁵

Water is also be transported from the luminal side of cells into the vasculature by aquaporin 3.⁷ Bisacodyl decreases expression of aquaporin 3, preventing water from moving into the vasculature, which may contribute to increased water in the colon.⁷

Bisacodyl directly stimulates parasympathetic nerves in the colon, stimulating contraction of longitudinal smooth muscle but not circular smooth muscle.^3,5

Target	Actions	Organism
UAquaporin-3	negative modulator	Humans
USodium/Potassium Transporting ATPase subunits	inhibitor	Humans

Absorption

Oral formulations of bisacodyl are only 16% bioavailable.^2,3 A 10 mg enteric coated oral tablet reaches a C_max of 26 ng/mL with a T_max of 8 hours, while a 10 mg oral solution reaches a C_max of 237 ng/mL with a T_max of 1.7 hours.¹⁰ A 10 mg suppository reaches a C_max of 0-64 ng/mL.¹⁰

In lactating women, 10mg of oral bisacodyl reaches a C_max of 20.5-195 ng/mL, with a T_max of 3-4 hours, and a geometric mean AUC after a single dose of 471 h*ng/mL.⁶ After multiple doses, the geometric mean AUC decreases to 311 h*ng/mL.⁶

Volume of distribution

Data regarding the volume of distribution of bisacodyl is not readily available. However, the volume of distribution of the active metabolite, BHPM, in lactating women is 181 L after a single dose and 289 L at steady state.⁶

Protein binding

Not Available

Metabolism

Bisacodyl is deacetylated to the active bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM) by an intestinal deacetylase.^4,5,6 A small amount of BHPM is absorbed from the gastrointestinal tract, and is glucuronidated before elimination.⁶

Hover over products below to view reaction partners

Bisacodyl
- Bis-(p-hydroxyphenyl)-pyridyl-2-methane

Route of elimination

The majority of bisacodyl is eliminated in the feces. 13.8-17.0% of a bisacodyl dose is eliminated in the urine as the active metabolite BHPM.⁶

Half-life

Data regarding the half life of bisacodyl is not readily available. The half life of the active metabolite, BHPM, in lactating women was 7.3 h after a single 10 mg oral dose and 10.0 h after multiple doses.⁶

Clearance

Data regarding the clearance of bisacodyl is not readily available. The apparent plasma clearance of the active metabolite, BHPM, in lactating women after a single 10 mg oral dose is 272 mL/min and after multiple doses is 412 mL/min.⁶

Adverse Effects

Improve decision support & research outcomes

With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.

Learn more

Improve decision support & research outcomes with our structured adverse effects data.

Learn more

Toxicity

Patients experiencing an overdose of bisacodyl may present with more severe diarrhea and electrolyte imbalance.¹ Patients should be treated with symptomatic and supportive measures.

The oral LD₅₀ in rats is 4320 mg/kg, and in mice is 17500 mg/kg.¹⁰

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

Drug	Interaction
Integrate drug-drug interactions in your software
Acetazolamide	The risk or severity of adverse effects can be increased when Acetazolamide is combined with Bisacodyl.
Aclidinium	The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Aclidinium.
Alfentanil	The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Alfentanil.
Alloin	The risk or severity of adverse effects can be increased when Bisacodyl is combined with Alloin.
Almasilate	The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Almasilate.
Aluminium	The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Aluminium.
Aluminium phosphate	The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Aluminium phosphate.
Aluminum hydroxide	The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Aluminum hydroxide.
Amantadine	The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Amantadine.
Amiloride	The risk or severity of adverse effects can be increased when Amiloride is combined with Bisacodyl.

Identify potential medication risks

Easily compare up to 40 drugs with our drug interaction checker.

Get severity rating, description, and management advice.

Learn more

Food Interactions

Avoid milk and dairy products. Take at least 1 hour before or after antacids and milk.
Take separate from antacids. Take at least 1 hour before or after antacids and milk.

Products

Drug product information from 10+ global regions

Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.

Access now

Access drug product information from over 10 global regions.

Access now

Active Moieties

Name	Kind	UNII	CAS	InChI Key
Deacetylbisacodyl	unknown	R09078E41Y	603-41-8	LJROKJGQSPMTKB-UHFFFAOYSA-N

Product Images

International/Other Brands

Bisalax (Actavis) / Bolax (Unifarma) / Boots Constipation Relief (Boots) / Derderance (Nisshin Seiyaku) / Dulco-Lax (Boehringer Ingelheim) / Dulcolaxo (Boehringer Ingelheim) / Fleet Laxative (Baxter) / Florisan (Boehringer Ingelheim) / Laxitab (Ranbaxy) / Reliable Gentle Laxative Tablets (Teva) / Spirolax / Verecolene C.M. (GlaxoSmithKline)

Brand Name Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Bisacodyl	Tablet	5 mg/1	Oral	Remedy Repack	2010-08-04	2012-07-01
Magic Bullet Laxative Suppository	Suppository	10 mg	Rectal	Smordins Dispensary Ltd.	Not applicable	Not applicable
Soflax EX Micro-enema	Enema; Suspension	2 mg / mL	Rectal	Pharmascience Inc	Not applicable	Not applicable

Over the Counter Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Ag-bisacodyl EC	Tablet	5 mg	Oral	Angita Pharma Inc.	Not applicable	Not applicable
Alophen	Tablet, coated	5 mg/1	Oral	Numark Brands, Inc	1907-04-15	Not applicable
Alophen Tablets	Tablet, delayed release	5 mg / tab	Oral	Numark Laboratories, Inc.	1998-08-31	2009-07-31
Amb-bisacodyl	Suppository	10 mg	Rectal	Ambicare Pharmaceuticals Inc.	Not applicable	Not applicable
Apo-bisacodyl	Tablet, delayed release	5 mg	Oral	Apotex Corporation	1982-12-31	Not applicable
Apo-bisacodyl Sup 10mg	Suppository	10 mg / sup	Rectal	Apotex Corporation	1988-12-31	Not applicable
APO-BISACODYL TABLET 5 mg	Tablet, coated	5 mg	Oral	PHARMAFORTE SINGAPORE PTE LTD	1988-12-28	Not applicable
Avedana Gentle Laxative	Suppository	10 mg/1	Rectal	Unipack, Inc.	2017-09-17	Not applicable
BEACOLUX TABLET 5MG ENTERIC COATED	Tablet, delayed release		Oral	DUOPHARMA MANUFACTURING (BANGI) SDN BHD	2020-09-08	Not applicable
Becolax Tablets	Tablet, delayed release	5 mg	Oral	Viva Pharmaceutical Inc.	Not applicable	Not applicable

Mixture Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End
BEKUNIS 3 MG/5 MG KAPLI TABLET, 30 ADET	Bisacodyl (3 mg) + Sennosides (5 mg)	Tablet, film coated	Oral	ABDİ İBRAHİM İLAÇ SAN. VE TİC. A.Ş.	2020-08-14	Not applicable
Bekunis Dragees	Bisacodyl (5 mg) + Senna leaf (60 mg) + Senna leaf (20 mg) + Senna leaf (25 mg)	Tablet	Oral	Roha Arzneimittel Gmbh	1974-12-31	2009-07-02
Bi-peglyte	Bisacodyl (5 mg / tab) + Polyethylene glycol (59.55 g / sachet) + Potassium chloride (0.76 g / sachet) + Sodium bicarbonate (1.69 g / sachet) + Sodium chloride (1.46 g / sachet) + Sodium sulfate (5.74 g / sachet)	Kit; Powder, for solution; Tablet, delayed release	Oral	Pendopharm Division Of Pharmascience Inc	2010-06-06	Not applicable
Bicholate Lilas	Bisacodyl (5 mg) + Aloe vera leaf (12 mg) + Frangula purshiana bark (30 mg) + Sodium taurocholate (60 mg)	Tablet	Oral	Sabex Inc	1998-10-28	2009-11-24
CHINTA-LAX	Bisacodyl (5 mg) + Docusate sodium (15 mg)	Tablet	Oral	WELLMEX SDN BHD	2020-09-08	2020-12-18
Dulcolax	Bisacodyl (5 mg/1) + Bisacodyl (10 mg/1)	Kit	Oral; Rectal	Boehringer Ingelheim	2003-04-01	2014-08-31
Dulcolax	Bisacodyl (5 mg/1) + Bisacodyl (10 mg/1)	Kit	Oral; Rectal	Boehringer Ingelheim	2003-04-01	2014-08-31
Dyrax-Q Tab	Bisacodyl (5 mg/161mg) + Docusate sodium (16.75 mg/161mg)	Tablet	Oral	Cho-A Pharm.Co.,Ltd.	2019-10-25	Not applicable
GaviLyte-H and Bisacodyl	Bisacodyl (5 mg/1) + Polyethylene glycol (210 g/2L) + Potassium chloride (0.74 g/2L) + Sodium bicarbonate (2.86 g/2L) + Sodium chloride (5.6 g/2L)	Kit	Oral	Lupin Pharmaceuticals, Inc.	2015-04-21	Not applicable
Gentlax S	Bisacodyl (5 mg) + Docusate sodium (50 mg)	Tablet	Oral	Purdue Pharma	2004-10-12	2011-08-04

Unapproved/Other Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End
Bisacodyl	Bisacodyl (10 mg/1)	Suppository	Rectal	Physicians Total Care, Inc.	2003-09-04	2013-01-15
Bisacodyl	Bisacodyl (5 mg/1)	Tablet	Oral	Remedy Repack	2010-08-04	2012-07-01
Bisacodyl	Bisacodyl (5 mg/1)	Tablet	Oral	Cardinal Health	2011-06-02	2011-10-31
PCP 100 Kit	Bisacodyl (5 mg/1) + Magnesium citrate (1.745 g/29.6mL) + Metoclopramide hydrochloride (10 mg/1) + Petrolatum (0.76 g/1g) + Polyethylene glycol (17 g/17g)	Kit	Oral	Asclemed Usa, Inc.	2014-01-02	Not applicable

Chemical Identifiers

UNII: 10X0709Y6I
CAS number: 603-50-9
InChI Key: KHOITXIGCFIULA-UHFFFAOYSA-N
InChI: InChI=1S/C22H19NO4/c1-15(24)26-19-10-6-17(7-11-19)22(21-5-3-4-14-23-21)18-8-12-20(13-9-18)27-16(2)25/h3-14,22H,1-2H3
IUPAC Name: 4-{[4-(acetyloxy)phenyl](pyridin-2-yl)methyl}phenyl acetate
SMILES: CC(=O)OC1=CC=C(C=C1)C(C1=CC=C(OC(C)=O)C=C1)C1=CC=CC=N1

References

Synthesis Reference

U.S. Patent 2,764,590.

General References

Kudo K, Miyazaki C, Kadoya R, Imamura T, Jitsufuchi N, Ikeda N: Laxative poisoning: toxicological analysis of bisacodyl and its metabolite in urine, serum, and stool. J Anal Toxicol. 1998 Jul-Aug;22(4):274-8. [Article]
Roth W, Beschke K: [Pharmacokinetics and laxative effect of bisacodyl following administration of various dosage forms]. Arzneimittelforschung. 1988 Apr;38(4):570-4. [Article]
Manabe N, Cremonini F, Camilleri M, Sandborn WJ, Burton DD: Effects of bisacodyl on ascending colon emptying and overall colonic transit in healthy volunteers. Aliment Pharmacol Ther. 2009 Nov 1;30(9):930-6. doi: 10.1111/j.1365-2036.2009.04118.x. Epub 2009 Aug 12. [Article]
Krueger D, Demir IE, Ceyhan GO, Zeller F, Schemann M: bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM)-the active metabolite of the laxatives bisacodyl and sodium picosulfate-enhances contractility and secretion in human intestine in vitro. Neurogastroenterol Motil. 2018 Jul;30(7):e13311. doi: 10.1111/nmo.13311. Epub 2018 Feb 14. [Article]
Lawrensia S, Raja A: Bisacodyl . [Article]
Friedrich C, Richter E, Trommeshauser D, de Kruif S, van Iersel T, Mandel K, Gessner U: Absence of excretion of the active moiety of bisacodyl and sodium picosulfate into human breast milk: an open-label, parallel-group, multiple-dose study in healthy lactating women. Drug Metab Pharmacokinet. 2011;26(5):458-64. doi: 10.2133/dmpk.dmpk-11-rg-007. Epub 2011 Jun 21. [Article]
Ikarashi N, Baba K, Ushiki T, Kon R, Mimura A, Toda T, Ishii M, Ochiai W, Sugiyama K: The laxative effect of bisacodyl is attributable to decreased aquaporin-3 expression in the colon induced by increased PGE2 secretion from macrophages. Am J Physiol Gastrointest Liver Physiol. 2011 Nov;301(5):G887-95. doi: 10.1152/ajpgi.00286.2011. Epub 2011 Aug 25. [Article]
US Patent: US2764590 [Link]
DailyMed:Bet-R-Prep (Bisacodyl) Oral Tablet [Link]
FDA Pharmacology Review: HalfLytely (Polyethylene Glycol-3350, Sodium Chloride, Sodium Bicarbonate, Potassium Chloride) Oral Solution and Bisacodyl Oral Tablet [Link]

External Links

KEGG Drug: D00245
PubChem Compound: 2391
PubChem Substance: 310264977
ChemSpider: 2299
BindingDB: 61400
RxNav: 1596
ChEBI: 3125
ChEMBL: CHEMBL942
ZINC: ZINC000003830321
Drugs.com: Drugs.com Drug Page
Wikipedia: Bisacodyl

FDA label

Download (62.7 KB)

MSDS

Download (495 KB)

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
4	Completed	Not Available	Bowel preparation therapy	1
4	Completed	Not Available	Colonoscopy	1
4	Completed	Diagnostic	Bowel Cleansing Quality	1
4	Completed	Other	Chronic Constipation	1
4	Completed	Prevention	Chronic Obstructive Pulmonary Disease (COPD)	1
4	Completed	Prevention	Thoracoabdominal Aortic Aneurysms	1
4	Completed	Supportive Care	Colonic Motility Index / Constipation	1
4	Completed	Treatment	Colon Cleansing	1
4	Completed	Treatment	Colonoscopy	6
4	Completed	Treatment	Colonoscopy Preparation	1

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Not Available

Dosage Forms

Form	Route	Strength
Tablet, film coated	Oral
Tablet	Topical	5 mg/1
Kit; powder, for solution; tablet, delayed release	Oral
Tablet, delayed release	Oral	5 m
Suppository	Rectal	0.01 g/2g
Tablet	Oral
Tablet, delayed release	Oral	5 mg/1
Suppository	Rectal	10 mg/1
Suppository	Rectal	5.0 mg
Tablet, delayed release	Oral	5 mg / tab
Tablet	Oral	5.0 mg
Tablet, coated	Oral	5 mg
Suppository	Rectal	10 mg
Suppository	Rectal	5 mg
Kit	Oral; Rectal
Tablet, coated	Oral	5 mg/1
Tablet, delayed release; tablet, film coated	Oral
Tablet, coated	Oral
Suppository	Rectal
Suspension	Rectal	10 mg / 5 mL
Suppository	Rectal	0.01 g
Tablet, coated	Oral	5.0000 mg
Tablet	Oral
Pill	Oral	5 mg/5mg
Tablet	Oral	5 mg/5mg
Enema	Rectal	10 mg/30mL
Kit	Oral
Tablet
Suppository	Rectal	10 mg / sup
Tablet, film coated	Oral	5 mg
Tablet	Oral	5 mg
Suppository	Rectal	10 mg/2000mg
Tablet, delayed release	Oral
Enema; suspension	Rectal	2 mg / mL
Suppository	Rectal	10 MG/G
Tablet	Oral	5 mg/1
Capsule, gelatin coated	Oral	5 mg/1
Tablet, film coated	Oral	5 mg/1
Tablet, sugar coated	Oral	5 mg/1
Tablet, coated	Oral
Tablet, sugar coated	Oral	5 mg
Tablet, coated	Oral	10 mg
Tablet, delayed release	Oral	5 mg
Capsule

Prices

Not Available

Patents

Patent Number	Pediatric Extension	Approved	Expires (estimated)	Region
US2764590	No	1953-03-16	1973-03-16
US7291324	No	2007-11-06	2022-10-22

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	138	U.S. Patent 2,764,590.

Predicted Properties

Property	Value	Source
Water Solubility	0.00127 mg/mL	ALOGPS
logP	4.71	ALOGPS
logP	3.61	ChemAxon
logS	-5.5	ALOGPS
pKa (Strongest Basic)	4.08	ChemAxon
Physiological Charge	0	ChemAxon
Hydrogen Acceptor Count	3	ChemAxon
Hydrogen Donor Count	0	ChemAxon
Polar Surface Area	65.49 Å²	ChemAxon
Rotatable Bond Count	7	ChemAxon
Refractivity	100.15 m³·mol^-1	ChemAxon
Polarizability	38.48 Å³	ChemAxon
Number of Rings	3	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	Yes	ChemAxon

Predicted ADMET Features

Not Available

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
LC-MS/MS Spectrum - LC-ESI-qTof , Positive	LC-MS/MS	Not Available
MS/MS Spectrum - , positive	LC-MS/MS	splash10-03e9-0619000000-408a755e5a908f9651a8
MS/MS Spectrum - , positive	LC-MS/MS	splash10-001i-2900000000-44bd4ec7df3de8de29aa

Targets

Build, predict & validate machine-learning models

Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.

Learn more

Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.

Learn more

Details1. Aquaporin-3

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Negative modulator

General Function: Water channel required to promote glycerol permeability and water transport across cell membranes. Acts as a glycerol transporter in skin and plays an important role in regulating SC (stratum corneum) and epidermal glycerol content. Involved in skin hydration, wound healing, and tumorigenesis. Provides kidney medullary collecting duct with high permeability to water, thereby permitting water to move in the direction of an osmotic gradient. Slightly permeable to urea and may function as a water and urea exit mechanism in antidiuresis in collecting duct cells. It may play an important role in gastrointestinal tract water transport and in glycerol metabolism (By similarity).
Specific Function: Glycerol channel activity
Gene Name: AQP3
Uniprot ID: Q92482
Uniprot Name: Aquaporin-3
Molecular Weight: 31543.605 Da

References

Ikarashi N, Baba K, Ushiki T, Kon R, Mimura A, Toda T, Ishii M, Ochiai W, Sugiyama K: The laxative effect of bisacodyl is attributable to decreased aquaporin-3 expression in the colon induced by increased PGE2 secretion from macrophages. Am J Physiol Gastrointest Liver Physiol. 2011 Nov;301(5):G887-95. doi: 10.1152/ajpgi.00286.2011. Epub 2011 Aug 25. [Article]
Rachmilewitz D, Karmeli F, Okon E: Effects of bisacodyl on cAMP and prostaglandin E2 contents, (Na + K) ATPase, adenyl cyclase, and phosphodiesterase activities of rat intestine. Dig Dis Sci. 1980 Aug;25(8):602-8. doi: 10.1007/BF01318874. [Article]
Schreiner J, Nell G, Loeschke K: Effect of diphenolic laxatives on Na+-K+-activated ATPase and cyclic nucleotide content of rat colon mucosa in vivo. Naunyn Schmiedebergs Arch Pharmacol. 1980 Sep;313(3):249-55. doi: 10.1007/BF00505741. [Article]

Details2. Sodium/Potassium Transporting ATPase subunits (Protein Group)

Kind: Protein group
Organism: Humans
Pharmacological action: Unknown
Actions: Inhibitor

General Function: Steroid hormone binding
Specific Function: This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane. This action creates th...

Components:

Name	UniProt ID
Sodium/potassium-transporting ATPase subunit alpha-1	P05023
Sodium/potassium-transporting ATPase subunit alpha-2	P50993
Sodium/potassium-transporting ATPase subunit alpha-3	P13637
Sodium/potassium-transporting ATPase subunit alpha-4	Q13733
Sodium/potassium-transporting ATPase subunit beta-1	P05026
Sodium/potassium-transporting ATPase subunit beta-2	P14415
Sodium/potassium-transporting ATPase subunit beta-3	P54709
Sodium/potassium-transporting ATPase subunit gamma	P54710

References

Schreiner J, Nell G, Loeschke K: Effect of diphenolic laxatives on Na+-K+-activated ATPase and cyclic nucleotide content of rat colon mucosa in vivo. Naunyn Schmiedebergs Arch Pharmacol. 1980 Sep;313(3):249-55. doi: 10.1007/BF00505741. [Article]

Drug created at June 24, 2014 17:03 / Updated at November 28, 2021 11:56

Bisacodyl

Identification

Structure for Bisacodyl (DB09020)

Pharmacology

Interactions

Products

Categories

Chemical Identifiers

References

Clinical Trials

Pharmacoeconomics

Properties

Spectra

Targets

References

Components:

References